CRIS Current Research Information System

BOLONDI, LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.533
EU - Europa 12.729
AS - Asia 12.157
AF - Africa 986
SA - Sud America 823
Continente sconosciuto - Info sul continente non disponibili 28
OC - Oceania 21
Totale 45.277
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.383
SG - Singapore 3.811
GB - Regno Unito 3.401
CN - Cina 3.269
VN - Vietnam 2.832
DE - Germania 1.794
IT - Italia 1.739
SE - Svezia 1.496
HK - Hong Kong 922
UA - Ucraina 791
RU - Federazione Russa 754
IN - India 688
FR - Francia 583
BR - Brasile 562
IE - Irlanda 520
NL - Olanda 356
ZA - Sudafrica 299
FI - Finlandia 282
EE - Estonia 259
TG - Togo 256
CH - Svizzera 242
CI - Costa d'Avorio 214
JP - Giappone 163
BG - Bulgaria 138
JO - Giordania 131
SC - Seychelles 95
AR - Argentina 92
CA - Canada 92
KR - Corea 85
BE - Belgio 82
NG - Nigeria 68
EC - Ecuador 65
ID - Indonesia 48
AT - Austria 45
PL - Polonia 45
MX - Messico 41
IR - Iran 39
GR - Grecia 37
ES - Italia 34
BD - Bangladesh 33
CL - Cile 31
HR - Croazia 31
RO - Romania 26
LT - Lituania 22
EU - Europa 21
CO - Colombia 19
IQ - Iraq 18
TR - Turchia 18
LB - Libano 15
PE - Perù 15
PY - Paraguay 14
UZ - Uzbekistan 14
MA - Marocco 13
AU - Australia 11
UY - Uruguay 11
EG - Egitto 10
MK - Macedonia 10
MY - Malesia 10
AE - Emirati Arabi Uniti 9
PK - Pakistan 8
VE - Venezuela 8
AM - Armenia 7
DO - Repubblica Dominicana 7
NZ - Nuova Zelanda 7
CZ - Repubblica Ceca 6
A2 - ???statistics.table.value.countryCode.A2??? 5
CR - Costa Rica 5
DZ - Algeria 5
NO - Norvegia 5
TW - Taiwan 5
DK - Danimarca 4
HU - Ungheria 4
IL - Israele 4
KE - Kenya 4
MU - Mauritius 4
NP - Nepal 4
PT - Portogallo 4
RS - Serbia 4
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
CG - Congo 3
KZ - Kazakistan 3
PH - Filippine 3
SI - Slovenia 3
SN - Senegal 3
SR - Suriname 3
TN - Tunisia 3
AL - Albania 2
ET - Etiopia 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
MM - Myanmar 2
OM - Oman 2
SA - Arabia Saudita 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BH - Bahrain 1
BN - Brunei Darussalam 1
Totale 45.255
Salva come PNG Salva come JPEG
Città #
Southend 3.061
Singapore 2.514
Fairfield 2.110
Ashburn 2.004
Chandler 1.501
Dong Ket 1.265
Houston 1.014
Wilmington 992
Woodbridge 982
Hong Kong 912
Seattle 887
Santa Clara 747
Ann Arbor 731
Cambridge 684
Princeton 676
Jacksonville 521
Dublin 519
Beijing 471
Boardman 411
Ho Chi Minh City 342
Westminster 312
Nanjing 308
Bologna 295
Hefei 277
Padova 274
Lomé 256
Munich 254
Hanoi 242
Helsinki 242
Berlin 216
Abidjan 214
Bern 213
Los Angeles 206
Jinan 161
Saint Petersburg 159
Tokyo 158
Buffalo 147
Shenyang 141
Sofia 138
New York 136
Dallas 132
Amman 131
Nanchang 117
Milan 115
San Diego 108
Medford 103
Turin 103
Changsha 99
Hebei 94
Redondo Beach 91
Mülheim 85
Brussels 79
Frankfurt am Main 78
Seoul 78
Guangzhou 76
Dearborn 75
Tianjin 74
Florence 72
Zhengzhou 69
Shanghai 68
Abeokuta 66
Jiaxing 58
Chicago 54
São Paulo 52
Bremen 50
Falls Church 50
Mahé 50
Haiphong 47
Ningbo 47
Redmond 46
Rome 46
Norwalk 45
Des Moines 44
Olalla 44
Redwood City 43
Phoenix 42
London 41
Toronto 39
Falkenstein 37
Yubileyny 36
Haikou 34
Hangzhou 34
Verona 33
Bühl 32
Da Nang 32
Mountain View 31
Amsterdam 29
Kunming 28
Taiyuan 28
Wuhan 28
Lanzhou 27
Nuremberg 27
Quito 26
Montreal 25
Paris 25
Turku 25
Guayaquil 24
Vienna 23
Pune 22
Taizhou 22
Totale 30.032
Salva come PNG Salva come JPEG
Nome #
Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study 387
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 380
Molecular Adsorbent Recirculating System (MARS) application in liver failure: Clinical and hemodepurative results in 22 patients 365
Efficacy of radioembolization according to tumor morphology and portal vein thrombosis inintermediate-advanced hepatocellular carcinoma 288
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study 287
Impiego del MARS nell'insufficienza epatica: efficacia depurativa e risultati clinici in 22 pazienti 281
A modeling study of bilirubin kinetics during Molecular Adsorbent Recirculating System sessions. 270
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 266
Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study 253
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 241
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 241
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) imaging for the diagnosis of cirrhosis during liver ultrasonography 240
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 237
A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. 236
Acute systemic, splanchnic and renal haemodynamic changes induced by molecular adsorbent recirculating system (MARS) treatment in patients with end-stage cirrhosis. 235
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 224
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 221
Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. 218
Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. 216
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma 214
Ablazione percutanea ecoguidata mediante radiofrequenza di piccoli noduli di HCC: fattori correlati all'esito clinico e alla recidiva di malattia 210
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. 208
Use of perfusional angiosonography in liver transplantation and conservative management of post-transplant intra-hepatic pseudo-aneurysm. 207
A new mathematical model for bilirubin kinetics during MARS sessions 206
Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study 204
Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. 198
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 193
LncRNAs as novel players in hepatocellular carcinoma recurrence 193
Analysis of risk factors for early hepatic artery thrombosis after liver transplantation. Possible contribution of reperfusion in the early morning. 191
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. 188
Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumors. 187
Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. 186
Nozioni di ecografia Doppler e color-Doppler 186
Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma 184
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 184
Reliability of imaging techniques in assessing portal venous thrombosis in patients with hepatocellular carcinoma candidates for liver transplantation 184
Affidabilità della combinazione di angioecografia perfusionale ed altre tecniche di imaging nella valutazione della trombosi portale in pazienti con epatocarcinoma (HCC) candidati al trapianto di fegato 184
Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. 184
Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted? 183
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 181
Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis 180
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 180
A case of inflammatory ascites. 180
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 180
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 178
Linee guida A.I.S.F. per l'ipertensione portale. 177
Quantification of enhancement of focal liver lesions during contrast-enhanced ultrasound (CEUS). Analysis of ten selected frames is more simple but as reliable as the analysis of the entire loop for most parameters. 177
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 177
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 176
Assessment of liver fibrosis in trnsplant recipients with recurrent HCV infection: Usefulness of transient elastography. 176
The rational use of albumin in patients with cirrhosis and ascites. A Delphi study for the attainment of a consensus on prescribing standards. 175
Characterization of focal liver lesions with contrast-enhanced ultrasound. 175
Venom from Cuban Blue Scorpion has tumor activating effect in hepatocellular carcinoma 174
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 174
Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register 174
Impiego clinico del “Fegato Artificiale” MARS: effetti sulle citochine e sui fattori di crescita 173
A case of intractable pruritus in Turner's syndrome successfully treated with molecular adsorbent recirculating system. 173
Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma (Scientific Reports (2017) 7 (44685) DOI: 10.1038/srep44685) 173
A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentation grade. 173
Celiac disease diagnosed through screening programs in at-risk adults is not associated with worse adherence to the gluten-free diet and might protect from osteopenia/osteoporosis 173
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 173
Binding of the doxorubicin-lactosaminated human albumin conjugate to HCC cells is mediated by the drug moieties. 172
Contrast-enhanced ultrasonography features of extramedullary hematopoiesis presenting as a presacral mass: an update of the literature. 171
Diagnostic features of real-time contrast-enhanced ultrasound in focal nodular hyperplasia of the liver. 171
Efficacy of doxorubicin coupled to lactosaminated albumin on rat hepatocellular carcinomas evaluated by ultrasound imaging. 171
Extracorporeal Detoxification for Hepatic Failure Using Molecular Adsorbent Recirculating System: Depurative Efficiency and Clinical Results in a Long-Term Follow-Up 171
CDKN1C/P57 Is Regulated by the Notch Target Gene Hes1 and Induces Senescence in Human Hepatocellular Carcinoma. 171
Contrast-enhanced ultrasonography to diagnose complicated acute cholecystitis 170
Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 169
Stadiazione epatica dei carcinomi gastrointestinali di prima diagnosi mediante angioecografia perfusionale. Confronto con TC spirale ed ecografia convenzionale. 168
Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. 168
ASSOCIATIONS OF THE -174 G/C INTERLEUKIN-6 GENE PROMOTER POLYMORPHISM WITH SERUM INTERLEUKIN -6 AND MORTALITY IN THE ELDERLY 167
Clinical application of artificial liver support with the Molecular Adsorbent Recirculating System (MARS): impact on cytokines and growth factors 167
Doxorubicin coupled to lactosaminated albumin: effect of heterogeneity in drug load on conjugate disposition and hepatocellular carcinoma uptake in rats. 166
Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer 165
Clinical and diagnostic aspects of gluten related disorders 165
Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. 165
Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. 165
Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging 165
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 165
null 164
Thorough assessment of portal venous thrombosis in patients with HCC allows adequate selection of candidates for liver transplantation 164
Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry 164
Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. 163
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma 162
Corrigendum to “Differences in liver stiffness values obtained with new ultrasound elastography machines and fibroscan: A comparative study” [Dig. Liver Dis. 49 (2017) 802–808](S1590865817302463)(10.1016/j.dld.2017.03.001) 162
Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study 161
A relative deficiency of lysosomal acid lypase activity characterizes non-alcoholic fatty liver disease 161
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. 161
Basi scientifiche per la definizione delle linee guida in ambito clinico per l’epatocarcinoma. 160
Doxorubicin coupled to lactosaminated human albumin: a hepatocellular carcinoma targeted drug. 160
Caution in the use of boldo in herbal laxatives: a case of hepatotoxicity. 159
Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. 158
Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma 158
Characterization of Small Nodules (1-3 cm) in Cirrhosis. The role of Perfusional Angiosonography, Spiral Computed Tomography and Double Contrast Magnetic Resonance 158
Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. 157
Role of Real-Time Contrast-Enhanced Ultrasound in the Assessment of Metastatic Portal Vein Thrombosis. 157
New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: A new diagnostic algorithm 157
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. 155
MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma 155
Totale 19.220
Salva come PNG Salva come JPEG
Categoria #
all - tutte 126.040
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 126.040
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.095 0 0 0 0 0 0 124 250 394 282 220 1.825
2021/20226.466 775 251 385 523 573 373 153 376 206 370 1.505 976
2022/20236.532 742 918 314 838 411 483 175 314 1.176 170 535 456
2023/20241.653 139 292 111 167 145 366 87 85 72 94 52 43
2024/20256.696 266 1.124 564 497 1.108 367 520 236 108 468 178 1.260
2025/20267.660 1.279 1.178 1.330 1.093 1.824 928 28 0 0 0 0 0
Totale 46.047